10x Genomics (TXG) Set to Post Earnings on Thursday

10x Genomics (NASDAQ:TXG) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.2670) per share and revenue of $147.96 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.10. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The firm had revenue of $151.04 million during the quarter, compared to the consensus estimate of $146.67 million. During the same period in the prior year, the firm earned $0.28 EPS. The company’s revenue was down 12.7% compared to the same quarter last year. On average, analysts expect 10x Genomics to post ($0.77) EPS for the current fiscal year and ($0.58) EPS for the next fiscal year.

10x Genomics Stock Down 12.1%

Shares of TXG stock opened at $61.63 on Tuesday. The firm has a market cap of $8.03 billion, a P/E ratio of -104.46 and a beta of 1.99. The company has a 50 day moving average of $74.10 and a 200-day moving average of $40.77. 10x Genomics has a 12-month low of $12.80 and a 12-month high of $102.81.

Analyst Ratings Changes

TXG has been the topic of several research reports. Royal Bank Of Canada assumed coverage on 10x Genomics in a research note on Tuesday, September 1st. They issued a “sector perform” rating and a $70.00 target price on the stock. TD Cowen increased their price target on 10x Genomics from $47.00 to $70.00 and gave the stock a “hold” rating in a research note on Tuesday, October 13th. Citigroup lifted their price objective on 10x Genomics from $45.00 to $50.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Morgan Stanley upped their price objective on shares of 10x Genomics from $40.00 to $70.00 and gave the company an “equal weight” rating in a report on Monday, October 12th. Finally, Stephens lowered shares of 10x Genomics from an “overweight” rating to an “equal weight” rating in a research report on Friday, October 23rd. Five research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $68.00.

Insider Transactions at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 13,818 shares of the business’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $63.02, for a total value of $870,810.36. Following the completion of the sale, the insider directly owned 488,182 shares of the company’s stock, valued at $30,765,229.64. The trade was a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director John R. Stuelpnagel sold 20,000 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $61.75, for a total value of $1,235,000.00. Following the sale, the director owned 328,436 shares of the company’s stock, valued at $20,280,923. This represents a 5.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 179,333 shares of company stock worth $11,810,070. Company insiders own 8.84% of the company’s stock.

About 10x Genomics

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.